Short stature caused by a biologically inactive mutant growth hormone (GH-C53S)

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 5, 2005, Pages 2493-2499

  Besson, Amélie ^a   Salemi, Souzan ^a   Deladoëy, Johnny ^a   Vuissoz, Jean Marc ^a   Eblé, Andrée ^a   Bidlingmaier, Martin ^c   Bürgi, Sibylle ^b   Honegger, Ulrich ^b   Flück, Christa ^a   Mullis, Primus E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; GROWTH HORMONE BINDING PROTEIN; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE; JANUS KINASE 2; LUCIFERASE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; STAT5 PROTEIN;

ADOLESCENT; ANIMAL CELL; ARTICLE; CASE REPORT; CHEMOLUMINESCENCE; CHO CELL; CONTROLLED STUDY; DISULFIDE BOND; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GH1 GENE; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HUMAN; IN VITRO STUDY; MALE; MISSENSE MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECEPTOR AFFINITY; SHORT STATURE; TRANSGENIC MOUSE; YUGOSLAVIA;

BODY HEIGHT; CHILD; DNA-BINDING PROTEINS; FEMALE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; JANUS KINASE 2; MALE; MILK PROTEINS; MUTATION, MISSENSE; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTORS, SOMATOTROPIN; STAT5 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

JANUS; MUS MUSCULUS;

EID: 21044435624     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1838     Document Type: Article

References (40)

1. Kowarski AA, Schneider J, Ben-Galim E, Weldon W, Daughaday WH 1978 Growth failure with normal serum RIA-GH and low somatomedin activity: somatomedin restoration and growth acceleration after exogenous GH. J Clin Endocrinol Metab 72:461-464
2. Hayek A, Peake GH 1978 A new syndrome of short stature due to biologically inactive but immunoreactive growth hormone. Pediatr Res 12:413
3. Rudman D, Kutner MH, Blackston RD, Cushman RA, Bain RP, Patterson JH 1981 Children with normal-variant short-stature: treatment with human growth hormone for six months. N Engl J Med 305:123-131
4. Frazer TE, Gavin JR, Daughaday WH, Hillman RE, Weldon VV 1982 Growth hormone dependent growth failure. J Pediatr 101:12-15
5. Plotnick LP, Van Meter QL, Kowarski AA 1983 Human growth hormone treatment of children with growth failure and normal growth hormone levels by immunoassay: lack of correlation with somatomedin generation. Pediatrics 71:324-327
6. Bright GM, Rogol AD, Johanson AJ, Blizzard RM 1983 Short stature associated with normal growth hormone and decreased somatomedin-C concentrations: response to exogenous growth hormone. Pediatrics 71:576-580
7. Takahashi Y, Shirono H, Arisaka O, Takahashi K, Yagi T, Koga J, Kaji H, Okimura Y, Abe H, Tanaka T, Chihara K 1997 Biologically inactive growth hormone caused by an amino acid substitution. J Clin Invest 100:1159-1165
8. Chihara K, Takahashi K, Kaji H, Goji K, Okimura Y, Abe H 1998 Short stature caused by natural growth hormone antagonist. Horm Res 49:41-45
9. Millar DS, Lewis MD, Horan M, Newsway V, Easter TE, Gregory JW, Fryklund L, Norin M, Crowne EC, Davies SJ, Edwards P, Kirk J, Waldron K, Smith PJ, Phillips III JA, Scanlon MF, Krawczak M, Cooper DN, Procter AM 2003 Novel mutations of the growth hormone 1 (GH1) gene disclosed by modulation of the clinical selection criteria for individuals with short stature. Hum Mutat 21:424-440
10. Wells JA 1996 Binding in the growth hormone receptor complex. Proc Natl Acad Sci USA 93:1-6
11. Herrington J, Carter-Su C 2001 Signaling pathways activated by the growth hormone receptor. Trends Endocrinol Metab 12:252-257
12. De Vos AM, Ultsch M, Kossiakoff AA 1992 Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255:306-312
13. Watahiki M, Yamamoto M, Yamakawa M, Tanaka T, Nakashima K 1989 Conserved and unique amino acid residues in the domains of the growth hormones. J Biol Chem 264:312-316
14. Nicoll CS, Mayer GL, Russell SM 1986 Structural features of prolactins and growth hormones that can be related to their biological properties. Endocr Rev 7:169-203
15. Kopchick JJ 2001 Growth and maturation. In: Melmed S, ed. Endocrinology. Philadelphia: W. B. Saunders Co.; 389-404
16. Chen XZ, Shafer AW, Yun JS, Li YS, Wagner TE, Kopchick JJ 1992 Conversion of bovine growth hormone cysteine residues to serine affects secretion by cultured cells and growth rates in transgenic mice. Mol Endocrinol 6:598-606
17. Graf L, Borvendeg J, Barat E, Hermann I, Patthy A 1976 Reactivity and biological importance of the disulfide bonds in human growth hormone. FEBS Lett 66:233-237
18. Graf L, Li CH, Bewley TA 1975 Selective reduction and alkylation of the COOH-terminal disulfide bridge in bovine growth hormone. Int J Pept Protein Res 7:467-473
19. Uchida E, Uemura H, Tanaka T, Nishikawa S, Uesugi S, Tanaka A, Morikawa M, Hayakawa T, Ikehara M 1991 Activity of artificial mutant variants of human growth hormone deficient in a disulfide bond between Cys 53 and Cys 165. Chem Pharm Bull (Tokyo) 39:150-153
20. Necessary PC, Andersen TT, Ebner KE 1985 Activity of alkylated prolactin and human growth hormone in receptor and cell assays. Mol Cell Endocrinol 39:247-254
21. Nutting DF, Kostyo JL, Mills JB, Wilhelmi AE 1970 A cyanogen bromide fragment of reduced and S-aminoethylated porcine growth hormone with anabolic activity. Biochim Biophys Acta 200:601-614
22. Dixon JS, Li CH 1966 Retention of the biological potency of human pituitary growth hormone after reduction and carbamidomethylation. Science 154:785-786
23. Campbell RM, Kostyo JL, Scanes CG 1990 Lipolytic and antilipolytic effects of human growth hormone, its 20-kilodalton variant, a reduced and carboxymethylated derivative, and human placental lactogen on chicken adipose tissue in vitro. Proc Soc Exp Biol Med 193:269-273
24. Trader A, Largo RH, Molinari L, Issler C 1989 Physical growth of Swiss children from birth to 20 years of age. Helv Paediatr Acta 52(Suppl):1-125
25. Buckway CK, Guevara-Aguirre J, Pratt KL, Burren CP, Rosenfeld RG 2001 The IGF-I generation test revisited: a marker of GH sensitivity. J Clin Endocrinol Metab 86:5176-5183
26. Marshall WA, Tanner JM 1970 Variations in pattern of pubertal changes in boys. Arch Dis Child 45:15-23
27. Greulich WW, Pyle SI 1959 Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Stanford, CA: Stanford University Press
28. Carlsson LM, Rosberg S, Vitangcol RV, Wong WL, Albertsson-Wikland K 1993 Analysis of 24-hour plasma profiles of growth hormone (GH)-binding protein, GH/GH-binding complex, and GH in healthy children. J Clin Endocrinol Metab 77:356-361
29. Deladoëy J, Stocker P, Mullis PE 2001 Autosomal dominant GH deficiency due to an Arg183His GH-1 gene mutation: clinical and molecular evidence of impaired regulated GH secretion. J Clin Endocrinol Metab 86:3941-3947
30. Strasburger CJ, Wu Z, Pflaum C-D, Dressendörfer RA 1996 Immunofunctional assay of human growth hormone (hGH) in serum: a possible consensus for quantitative hGH measurement. J Clin Endocrinol Metab 81:2613-2620
31. Maamra M, Finidori J, von Laue S, Simon S, Justice S, Webster J, Dower S, Ross RJ 1999 Studies with a growth hormone antagonist and dual-fluorescent confocal microscopy demonstrate that the full-length human growth hormone receptor, but not the truncated isoform, is very rapidly internalized independent of Jak2-Stat5 signaling. J Biol Chem 274:14791-14798
32. Von Laue S, Finidori J, Maamra M, Shen XY, Justice S, Dobson PR, Ross RJ 2000 Stimulation of endogenous GH and interleukin-6 receptors selectively activates different Jaks and Stats, with a Stat5 specific synergistic effect of dexamethasone. J Endocrinol 165:301-311
33. Ross RJ, Esposito N, Shen XY, von Laue S, Chew SL, Dobson PR, Postel-Vinay MC, Finidori J 1997 A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein. Mol Endocrinol 11:265-273
34. Sotiropoulos A, Moutoussamy S, Renaudie F, Clauss M, Kayser C, Gouilleux F, Kelly PA, Finidori J 1996 Differential activation of Stat3 and Stat5 by distinct regions of the growth hormone receptor. Mol Endocrinol 10:998-1009
35. Moutoussamy S, Kelly PA, Finidori J 1998 Growth-hormone-receptor and cytokine-receptor-family signaling. Eur J. Biochem 255:1-11
36. Daughaday WH, Laron Z, Pertzelan A, Heins JN 1969 Defective sulfation factor generation: a possible etiological link in dwarfism. Trans Assoc Am Physicians 82:129-138
37. Laron Z, Pertzelan A, Karp M, Kowaldo-Silbergeld A, Daughaday WH 1971 Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone. Measurement of sulfation factor, metabolic, and linear growth responses. J Clin Endocrinol Metab 33:332-342
38. Cunningham BC, Wells JA 1989 High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 244:1081-1085
39. Rosenfeld RG, Hwa V 2004 Toward a molecular basis for idiopathic short stature. J Clin Endocrinol Metab 89:1066-1067
40. Lewis MD, Horan M, Millar DS, Newsway V, Easter TE, Fryklund L, Gregory JW, Norin M, Del Valle C-J, Lopez-Siguero JP, Canete R, Lopez-Canti LF, Diaz-Torrado N, Espino R, Ulied A, Scanlon MF, Procter AM, Cooper DN 2004 A novel dysfunctional growth hormone variant (Ile179Met) exhibits a decreased ability to activate the extracellular signal-regulated kinase pathway. J Clin Endocrinol Metab 89:1068-1075